在透析患者群体中,脂质和全因死亡率之间的剂量反应关系:元分析
Ye Yao1, Jing Xiong2, Mi-Yuan Wang3
1Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
BMC nephrology
|February 5, 2025
概括
总胆固醇 (TC) 水平在180-220 mg/dL之间与透析患者全因死亡率降低有关. 增加的甘油三 (TG) 在这一群体中显著增加死亡风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管医学 心血管医学
- 临床流行病学临床流行病学
背景情况:
- 在透析患者中降脂疗法的作用仍然存在争议,因为缺乏确定的目标.
- 现有的指导方针没有为接受透析的个体提供具体的脂质标.
研究的目的:
- 在透析患者群体中调查各种脂质参数和全因死亡率之间的剂量反应关系.
- 确定最佳的脂质水平范围,以减少透析患者的死亡风险.
主要方法:
- 对已发表的队列研究进行了全面的元分析,使用了主要科学数据库的数据,直到2023年2月.
- 包括的研究集中在脂质与透析患者全因死亡率之间的关联.
- 使用Stata 17.0.0进行了统计分析,包括剂量反应建模.
主要成果:
- 对11项研究 (106,808人) 的分析显示,总胆固醇 (TC) > 140.5 mg/dL与较低的全因死亡率有关.
- 在透析患者中降低死亡率的最佳TC范围被确定为180-220 mg/dL.
- 高甘油 (TG) 与全因死亡率呈正相关性 (每50mg/dL增加2.5%的增加),而非高密度脂蛋白胆固醇 (NHDL-C) 和低密度脂蛋白胆固醇 (LDL-C) 没有明显的相关性.
结论:
- 总胆固醇 (TC) 是监测透析患者的临床相关目标,其水平为180-220 mg/dL,与所有原因死亡率最低相关.
- 监测NHDL-C和LDL-C在这个人群中不被认为具有临床意义.
- 增加的TG水平是透析患者因所有原因死亡率较高的重要风险因素.
相关概念视频
01:11Renal Failure: Dose Adjustments
675
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
675
01:21Drug Dosing: Obese Patients
372
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
372
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
342
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
342
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
374
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
374
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
268
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
268
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
126
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
126